Alnylam Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.About ALNY
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference.
CEOYvonne L. Greenstreet
CEOYvonne L. Greenstreet
Employees2,230
Employees2,230
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded2002
Founded2002
Employees2,230
Employees2,230
ALNY Key Statistics
Market cap41.79B
Market cap41.79B
Price-Earnings ratio-155.14
Price-Earnings ratio-155.14
Dividend yield—
Dividend yield—
Average volume884.52K
Average volume884.52K
High today$325.62
High today$325.62
Low today$317.88
Low today$317.88
Open price$325.62
Open price$325.62
Volume580.52K
Volume580.52K
52 Week high$333.70
52 Week high$333.70
52 Week low$205.87
52 Week low$205.87
ALNY News
TipRanks 2d
Alnylam’s ELEVATE Study: A Closer Look at AHP Treatment AdvancementsAlnylam Pharmaceuticals ((ALNY)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 5...
TipRanks 3d
Alnylam price target raised to $348 from $338 at JPMorganJPMorgan analyst Jessica Fye raised the firm’s price target on Alnylam (ALNY) to $348 from $338 and keeps an Overweight rating on the shares. The firm increased...
Analyst ratings
71%
of 34 ratingsBuy
70.6%
Hold
26.5%
Sell
2.9%
People also own
Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.